

# Global Circulating Tumor Cells Market Analysis and Forecast 2024-2030

<https://marketpublishers.com/r/G5B3CB78A427EN.html>

Date: April 2024

Pages: 138

Price: US\$ 4,950.00 (Single User License)

ID: G5B3CB78A427EN

## Abstracts

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

According to APO Research, The global Circulating Tumor Cells market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen?Adnagen?, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.

### Report Includes

This report presents an overview of global market for Circulating Tumor Cells, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Circulating Tumor Cells, also provides the revenue of main regions and countries. Of the upcoming market potential for Circulating Tumor Cells, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Circulating Tumor Cells revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Circulating Tumor Cells market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Circulating Tumor Cells revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Menarini-Silicon Biosystems, Qiagen (Adnagen), Advanced Cell Diagnostics, ApoCell, Epic Sciences, Greiner Bio-one GmbH, Cynvenio, SurExamBio-Tech and Fluxion Biosciences, etc.

#### Circulating Tumor Cells segment by Company

Menarini-Silicon Biosystems

Qiagen (Adnagen)

Advanced Cell Diagnostics

ApoCell

Epic Sciences

Greiner Bio-one GmbH

Cynvenio

SurExamBio-Tech

Fluxion Biosciences

Ikonisys

Hangzhou Watson Biotech

Biocept

CytoTrack

Guangzhou Wondfo Biotech

Celsee

Clearbridge Biomedics

ANGLE plc

#### Circulating Tumor Cells segment by Type

CTC Enrichment

CTC Detection

CTC Analysis

#### Circulating Tumor Cells segment by Application

Breast Cancer

Prostate Cancer

Colorectal Cancer

Lung Cancer

Others

#### Circulating Tumor Cells segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

### Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

### Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells market, and introduces in detail the market share, industry ranking, competitor

ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Circulating Tumor Cells in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development

prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cells revenue, gross margin, and recent development, etc.

Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

Chapter 13: The main concluding insights of the report.

## Contents

### **1 MARKET OVERVIEW**

- 1.1 Product Definition
- 1.2 Circulating Tumor Cells Market by Type
  - 1.2.1 Global Circulating Tumor Cells Market Size by Type, 2019 VS 2023 VS 2030
  - 1.2.2 CTC Enrichment
  - 1.2.3 CTC Detection
  - 1.2.4 CTC Analysis
- 1.3 Circulating Tumor Cells Market by Application
  - 1.3.1 Global Circulating Tumor Cells Market Size by Application, 2019 VS 2023 VS 2030
  - 1.3.2 Breast Cancer
  - 1.3.3 Prostate Cancer
  - 1.3.4 Colorectal Cancer
  - 1.3.5 Lung Cancer
  - 1.3.6 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

### **2 CIRCULATING TUMOR CELLS MARKET DYNAMICS**

- 2.1 Circulating Tumor Cells Industry Trends
- 2.2 Circulating Tumor Cells Industry Drivers
- 2.3 Circulating Tumor Cells Industry Opportunities and Challenges
- 2.4 Circulating Tumor Cells Industry Restraints

### **3 GLOBAL GROWTH PERSPECTIVE**

- 3.1 Global Circulating Tumor Cells Market Perspective (2019-2030)
- 3.2 Global Circulating Tumor Cells Growth Trends by Region
  - 3.2.1 Global Circulating Tumor Cells Market Size by Region: 2019 VS 2023 VS 2030
  - 3.2.2 Global Circulating Tumor Cells Market Size by Region (2019-2024)
  - 3.2.3 Global Circulating Tumor Cells Market Size by Region (2025-2030)

### **4 COMPETITIVE LANDSCAPE BY PLAYERS**

- 4.1 Global Circulating Tumor Cells Revenue by Players



- 4.1.1 Global Circulating Tumor Cells Revenue by Players (2019-2024)
- 4.1.2 Global Circulating Tumor Cells Revenue Market Share by Players (2019-2024)
- 4.1.3 Global Circulating Tumor Cells Players Revenue Share Top 10 and Top 5 in 2023
- 4.2 Global Circulating Tumor Cells Key Players Ranking, 2022 VS 2023 VS 2024
- 4.3 Global Circulating Tumor Cells Key Players Headquarters & Area Served
- 4.4 Global Circulating Tumor Cells Players, Product Type & Application
- 4.5 Global Circulating Tumor Cells Players Commercialization Time
- 4.6 Market Competitive Analysis
  - 4.6.1 Global Circulating Tumor Cells Market CR5 and HHI
  - 4.6.2 Global Top 5 and 10 Circulating Tumor Cells Players Market Share by Revenue in 2023
  - 4.6.3 2023 Circulating Tumor Cells Tier 1, Tier 2, and Tier

## **5 CIRCULATING TUMOR CELLS MARKET SIZE BY TYPE**

- 5.1 Global Circulating Tumor Cells Revenue by Type (2019 VS 2023 VS 2030)
- 5.2 Global Circulating Tumor Cells Revenue by Type (2019-2030)
- 5.3 Global Circulating Tumor Cells Revenue Market Share by Type (2019-2030)

## **6 CIRCULATING TUMOR CELLS MARKET SIZE BY APPLICATION**

- 6.1 Global Circulating Tumor Cells Revenue by Application (2019 VS 2023 VS 2030)
- 6.2 Global Circulating Tumor Cells Revenue by Application (2019-2030)
- 6.3 Global Circulating Tumor Cells Revenue Market Share by Application (2019-2030)

## **7 COMPANY PROFILES**

- 7.1 Menarini-Silicon Biosystems
  - 7.1.1 Menarini-Silicon Biosystems Company Information
  - 7.1.2 Menarini-Silicon Biosystems Business Overview
  - 7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (2019-2024)
  - 7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio
  - 7.1.5 Menarini-Silicon Biosystems Recent Developments
- 7.2 Qiagen (Adnagen)
  - 7.2.1 Qiagen (Adnagen) Company Information
  - 7.2.2 Qiagen (Adnagen) Business Overview
  - 7.2.3 Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin

(2019-2024)

7.2.4 Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio

7.2.5 Qiagen (Adnagen) Recent Developments

7.3 Advanced Cell Diagnostics

7.3.1 Advanced Cell Diagnostics Company Information

7.3.2 Advanced Cell Diagnostics Business Overview

7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin

(2019-2024)

7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio

7.3.5 Advanced Cell Diagnostics Recent Developments

7.4 ApoCell

7.4.1 ApoCell Company Information

7.4.2 ApoCell Business Overview

7.4.3 ApoCell Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.4.4 ApoCell Circulating Tumor Cells Product Portfolio

7.4.5 ApoCell Recent Developments

7.5 Epic Sciences

7.5.1 Epic Sciences Company Information

7.5.2 Epic Sciences Business Overview

7.5.3 Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.5.4 Epic Sciences Circulating Tumor Cells Product Portfolio

7.5.5 Epic Sciences Recent Developments

7.6 Greiner Bio-one GmbH

7.6.1 Greiner Bio-one GmbH Company Information

7.6.2 Greiner Bio-one GmbH Business Overview

7.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin

(2019-2024)

7.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio

7.6.5 Greiner Bio-one GmbH Recent Developments

7.7 Cynvenio

7.7.1 Cynvenio Company Information

7.7.2 Cynvenio Business Overview

7.7.3 Cynvenio Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.7.4 Cynvenio Circulating Tumor Cells Product Portfolio

7.7.5 Cynvenio Recent Developments

7.8 SurExamBio-Tech

7.8.1 SurExamBio-Tech Company Information

7.8.2 SurExamBio-Tech Business Overview

7.8.3 SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin

(2019-2024)

7.8.4 SurExamBio-Tech Circulating Tumor Cells Product Portfolio

7.8.5 SurExamBio-Tech Recent Developments

7.9 Fluxion Biosciences

7.9.1 Fluxion Biosciences Company Information

7.9.2 Fluxion Biosciences Business Overview

7.9.3 Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin

(2019-2024)

7.9.4 Fluxion Biosciences Circulating Tumor Cells Product Portfolio

7.9.5 Fluxion Biosciences Recent Developments

7.10 Ikonisys

7.10.1 Ikonisys Company Information

7.10.2 Ikonisys Business Overview

7.10.3 Ikonisys Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.10.4 Ikonisys Circulating Tumor Cells Product Portfolio

7.10.5 Ikonisys Recent Developments

7.11 Hangzhou Watson Biotech

7.11.1 Hangzhou Watson Biotech Company Information

7.11.2 Hangzhou Watson Biotech Business Overview

7.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Revenue and Gross Margin

(2019-2024)

7.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio

7.11.5 Hangzhou Watson Biotech Recent Developments

7.12 Biocept

7.12.1 Biocept Company Information

7.12.2 Biocept Business Overview

7.12.3 Biocept Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.12.4 Biocept Circulating Tumor Cells Product Portfolio

7.12.5 Biocept Recent Developments

7.13 CytoTrack

7.13.1 CytoTrack Company Information

7.13.2 CytoTrack Business Overview

7.13.3 CytoTrack Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.13.4 CytoTrack Circulating Tumor Cells Product Portfolio

7.13.5 CytoTrack Recent Developments

7.14 Guangzhou Wondfo Biotech

7.14.1 Guangzhou Wondfo Biotech Company Information

7.14.2 Guangzhou Wondfo Biotech Business Overview

7.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue and Gross

## Margin (2019-2024)

7.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio

7.14.5 Guangzhou Wondfo Biotech Recent Developments

## 7.15 Celsee

7.15.1 Celsee Company Information

7.15.2 Celsee Business Overview

7.15.3 Celsee Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.15.4 Celsee Circulating Tumor Cells Product Portfolio

7.15.5 Celsee Recent Developments

## 7.16 Clearbridge Biomedics

7.16.1 Clearbridge Biomedics Company Information

7.16.2 Clearbridge Biomedics Business Overview

7.16.3 Clearbridge Biomedics Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.16.4 Clearbridge Biomedics Circulating Tumor Cells Product Portfolio

7.16.5 Clearbridge Biomedics Recent Developments

## 7.17 ANGLE plc

7.17.1 ANGLE plc Company Information

7.17.2 ANGLE plc Business Overview

7.17.3 ANGLE plc Circulating Tumor Cells Revenue and Gross Margin (2019-2024)

7.17.4 ANGLE plc Circulating Tumor Cells Product Portfolio

7.17.5 ANGLE plc Recent Developments

## **8 NORTH AMERICA**

8.1 North America Circulating Tumor Cells Revenue (2019-2030)

8.2 North America Circulating Tumor Cells Revenue by Type (2019-2030)

8.2.1 North America Circulating Tumor Cells Revenue by Type (2019-2024)

8.2.2 North America Circulating Tumor Cells Revenue by Type (2025-2030)

8.3 North America Circulating Tumor Cells Revenue Share by Type (2019-2030)

8.4 North America Circulating Tumor Cells Revenue by Application (2019-2030)

8.4.1 North America Circulating Tumor Cells Revenue by Application (2019-2024)

8.4.2 North America Circulating Tumor Cells Revenue by Application (2025-2030)

8.5 North America Circulating Tumor Cells Revenue Share by Application (2019-2030)

8.6 North America Circulating Tumor Cells Revenue by Country

8.6.1 North America Circulating Tumor Cells Revenue by Country (2019 VS 2023 VS 2030)

8.6.2 North America Circulating Tumor Cells Revenue by Country (2019-2024)

8.6.3 North America Circulating Tumor Cells Revenue by Country (2025-2030)

8.6.4 U.S.

8.6.5 Canada

## **9 EUROPE**

9.1 Europe Circulating Tumor Cells Revenue (2019-2030)

9.2 Europe Circulating Tumor Cells Revenue by Type (2019-2030)

9.2.1 Europe Circulating Tumor Cells Revenue by Type (2019-2024)

9.2.2 Europe Circulating Tumor Cells Revenue by Type (2025-2030)

9.3 Europe Circulating Tumor Cells Revenue Share by Type (2019-2030)

9.4 Europe Circulating Tumor Cells Revenue by Application (2019-2030)

9.4.1 Europe Circulating Tumor Cells Revenue by Application (2019-2024)

9.4.2 Europe Circulating Tumor Cells Revenue by Application (2025-2030)

9.5 Europe Circulating Tumor Cells Revenue Share by Application (2019-2030)

9.6 Europe Circulating Tumor Cells Revenue by Country

9.6.1 Europe Circulating Tumor Cells Revenue by Country (2019 VS 2023 VS 2030)

9.6.2 Europe Circulating Tumor Cells Revenue by Country (2019-2024)

9.6.3 Europe Circulating Tumor Cells Revenue by Country (2025-2030)

9.6.4 Germany

9.6.5 France

9.6.6 U.K.

9.6.7 Italy

9.6.8 Russia

## **10 CHINA**

10.1 China Circulating Tumor Cells Revenue (2019-2030)

10.2 China Circulating Tumor Cells Revenue by Type (2019-2030)

10.2.1 China Circulating Tumor Cells Revenue by Type (2019-2024)

10.2.2 China Circulating Tumor Cells Revenue by Type (2025-2030)

10.3 China Circulating Tumor Cells Revenue Share by Type (2019-2030)

10.4 China Circulating Tumor Cells Revenue by Application (2019-2030)

10.4.1 China Circulating Tumor Cells Revenue by Application (2019-2024)

10.4.2 China Circulating Tumor Cells Revenue by Application (2025-2030)

10.5 China Circulating Tumor Cells Revenue Share by Application (2019-2030)

## **11 ASIA (EXCLUDING CHINA)**

11.1 Asia Circulating Tumor Cells Revenue (2019-2030)

- 11.2 Asia Circulating Tumor Cells Revenue by Type (2019-2030)
  - 11.2.1 Asia Circulating Tumor Cells Revenue by Type (2019-2024)
  - 11.2.2 Asia Circulating Tumor Cells Revenue by Type (2025-2030)
- 11.3 Asia Circulating Tumor Cells Revenue Share by Type (2019-2030)
- 11.4 Asia Circulating Tumor Cells Revenue by Application (2019-2030)
  - 11.4.1 Asia Circulating Tumor Cells Revenue by Application (2019-2024)
  - 11.4.2 Asia Circulating Tumor Cells Revenue by Application (2025-2030)
- 11.5 Asia Circulating Tumor Cells Revenue Share by Application (2019-2030)
- 11.6 Asia Circulating Tumor Cells Revenue by Country
  - 11.6.1 Asia Circulating Tumor Cells Revenue by Country (2019 VS 2023 VS 2030)
  - 11.6.2 Asia Circulating Tumor Cells Revenue by Country (2019-2024)
  - 11.6.3 Asia Circulating Tumor Cells Revenue by Country (2025-2030)
  - 11.6.4 Japan
  - 11.6.5 South Korea
  - 11.6.6 India
  - 11.6.7 Australia
  - 11.6.8 China Taiwan
  - 11.6.9 Southeast Asia

## **12 MIDDLE EAST, AFRICA, LATIN AMERICA**

- 12.1 MEALA Circulating Tumor Cells Revenue (2019-2030)
- 12.2 MEALA Circulating Tumor Cells Revenue by Type (2019-2030)
  - 12.2.1 MEALA Circulating Tumor Cells Revenue by Type (2019-2024)
  - 12.2.2 MEALA Circulating Tumor Cells Revenue by Type (2025-2030)
- 12.3 MEALA Circulating Tumor Cells Revenue Share by Type (2019-2030)
- 12.4 MEALA Circulating Tumor Cells Revenue by Application (2019-2030)
  - 12.4.1 MEALA Circulating Tumor Cells Revenue by Application (2019-2024)
  - 12.4.2 MEALA Circulating Tumor Cells Revenue by Application (2025-2030)
- 12.5 MEALA Circulating Tumor Cells Revenue Share by Application (2019-2030)
- 12.6 MEALA Circulating Tumor Cells Revenue by Country
  - 12.6.1 MEALA Circulating Tumor Cells Revenue by Country (2019 VS 2023 VS 2030)
  - 12.6.2 MEALA Circulating Tumor Cells Revenue by Country (2019-2024)
  - 12.6.3 MEALA Circulating Tumor Cells Revenue by Country (2025-2030)
  - 12.6.4 Mexico
  - 12.6.5 Brazil
  - 12.6.6 Israel
  - 12.6.7 Argentina
  - 12.6.8 Colombia

12.6.9 Turkey

12.6.10 Saudi Arabia

12.6.11 UAE

## **13 CONCLUDING INSIGHTS**

## **14 APPENDIX**

14.1 Reasons for Doing This Study

14.2 Research Methodology

14.3 Research Process

14.4 Authors List of This Report

14.5 Data Source

14.5.1 Secondary Sources

14.5.2 Primary Sources

14.6 Disclaimer

## I would like to order

Product name: Global Circulating Tumor Cells Market Analysis and Forecast 2024-2030

Product link: <https://marketpublishers.com/r/G5B3CB78A427EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5B3CB78A427EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970